期刊文献+

Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-α 被引量:2

Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-α
下载PDF
导出
摘要 AIM: To evaluate the prevalence of autoantibodies in chronic hepatitis C virus (HCV)-infected children focusing on thyroid autoimmunity.METHODS: We investigated the prevalence of autoantibodies in 123 chronic HCV-infected children before, during and after monotherapy with interferon-alpha (IFN-α) or combined treatment with interferon-α or peginterferon-α and ribavirin. Besides antibodies against smooth muscle (SMA), nuclei (ANA), and liver/kidney microsomes (1KM), the incidence of antithyroid peroxidase antibodies as well as thyroid function parameters (TSH, FT3 and FT4) were determined.RESULTS: We found that 8% of children had autoantibodies before treatment. During treatment, 18% of children were found positive for at least one autoantibody; 15.5% of children developed pathologic thyroid values during IFN-α treatment compared to only one child before therapy. Six children had to be substituted while developing laboratory signs of hypothyroidism.CONCLUSION: Our data indicate a strong correlation between interferon-α treatment and autoimmune phenomena, notably the emergence of thyroid antibodies. The fact that some children required hormone replacement underlines the need of close monitoring in particularly those who respond to therapy and have to be treated for more than 6 mo. AIM: To evaluate the prevalence of autoantibodies in chronic hepatitis C virus (HCV)-infected children focusing on thyroid autoimmunity. METHODS: We investigated the prevalence of auto- antibodies in 123 chronic HCV-infected children before, during and after monotherapy with interferon-alpha (IFN-α) or combined treatment with interferon-α or peginterferon-α and ribavirin. Besides antibodies against smooth muscle (SMA), nuclei (ANA), and liver/kidney microsomes (LKM), the incidence of anti- thyroid peroxidase antibodies as well as thyroid function parameters (TSH, FT3 and FT4) were determined. RESULTS: We found that 8% of children had autoantibodies before treatment. During treatment, 18% of children were found positive for at least one autoantibody; 15.5% of children developed pathologic thyroid values during IFN-α treatment compared to only one child before therapy. Six children had to be substituted while developing laboratory signs of hypothyroidism. CONCLUSION: Our data indicate a strong correlation between interferon-α treatment and autoimmune phenomena, notably the emergence of thyroid antibodies. The fact that some children required hormone replacement underlines the need of close monitoring in particularly those who respond to therapy and have to be treated for more than 6 mo.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第36期5787-5792,共6页 世界胃肠病学杂志(英文版)
关键词 Hepatitis C treatment CHILDREN Thyroiddysfunction AUTOANTIBODIES 自身抗体 甲状腺疾病 自身免疫 慢性丙性肝炎
  • 相关文献

参考文献28

  • 1[1]Farci P,Choo QL,Kuo G,Weiner AJ,Overby LR,Bradley DW,Houghton M.Isolation of a cDNA clone derived from a bloodborne non-A,non-B viral hepatitis genome.J Hepatol 2002; 36:582-585
  • 2[2]Wasmuth HE,Stolte C,Geier A,Dietrich CG,Gartung C,Lorenzen J,Matern S,Lammert F.The presence of non-organspecific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C.BMC Infect Dis 2004; 4:4
  • 3[3]Lenzi M,Bellentani S,Saccoccio G,Muratori P,Masutti F,Muratori L,Cassani F,Bianchi FB,Tiribelli C.Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population:a nested case-control study of the Dionysos cohort.Gut 1999; 45:435-441
  • 4[4]Cassani F,Cataleta M,Valentini P,Muratori P,Giostra F,Francesconi R,Muratori L,Lenzi M,Bianchi G,Zauli D,Bianchi FB.Serum autoantibodies in chronic hepatitis C:comparison with autoimmune hepatitis and impact on the disease profile.Hepatology 1997; 26:561-566
  • 5[5]Clifford BD,Donahue D,Smith L,Cable E,Luttig B,Manns M,Bonkovsky HL.High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C.Hepatology 1995; 21:613-619
  • 6[6]Todros L,Saracco G,Durazzo M,Abate ML,Touscoz G,Scaglione L,Verme G,Rizzetto M.Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes.Hepatology 1995;22:1374-1378
  • 7[7]Gregorio GV,Pensati P,Iorio R,Vegnente A,Mieli-Vergani G,Vergani D.Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection.Clin Exp Immunol 1998; 112:471-476
  • 8[8]Schiano TD,Te HS,Thomas RM,Hussain H,Bond K,Black M.Results of.steroid-based therapy for the hepatitis C-autoimmune hepatitis overlap syndrome.Am J Gastroenterol 2001; 96:2984-2991
  • 9[9]Wilson LE,Widman D,Dikman SH,Gorevic PD.Autoimmune disease complicating antiviral therapy for hepatitis C virus infection.Semin Arthritis Rheum 2002; 32:163-173
  • 10[10]Manns MP,Rambusch EG.Autoimmunity and extrahepatic manifestations in hepatitis C virus infection.J Hepatol 1999; 31Suppl 1:39-42

同被引文献2

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部